MedTrace Logo

Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

NCT01743027 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 902

Last updated 2014-08-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AL-4943A ophthalmic solution

DRUG

Olopatadine hydrochloride ophthalmic solution, 0.2%

DRUG

Olopatadine hydrochloride ophthalmic solution, 0.1%

DRUG

AL-4943A ophthalmic solution vehicle

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Abhijit Narvekar, MS, MBBS · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-07-31
Completion
2013-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01743027 on ClinicalTrials.gov